Resveratrol inhibits inducible nitric oxide synthase and cyclooxygenase-2 expression in β-amyloid-treated C6 glioma cells
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Resveratrol has been reported to exert a variety of important pharmacological effects including anti-inflammatory, cardioprotective and cancer chemopreventive properties; however, its mechanisms of action are not completely under-stood. beta-amyloid protein is considered to be responsible for the formation of senile plaques that accumulate in the brains of patients with Alzheimer disease. In the present study, we investigated the protective effect of resveratrol on beta-amyloid-induced cytoxicity in cultured rat astroglioma C6 cells. Preincubation of C6 cells with resveratrol concentration-dependently protected the cells from the growth inhibition induced by beta-amyloid treatment. beta-amyloid treatment led to increased nitric oxide (NO) synthesis and inducible nitric oxide synthase (iNOS) expression; however, cells pretreated with resveratrol showed a dose-dependent inhibition of NO production and iNOS expression following beta-amyloid treatment. Resveratrol also attenuated beta-amyloid-induced prostaglandin E2 (PGE2) release, which was associated with the inhibition of cyclooxygenase (COX)-2 expression. Furthermore, beta-amyloid treatment induced nuclear translocation of NF-kappaB, which was suppressed by resveratrol pretreatment. Collectively, the present results indicate that modulation of nuclear factor-kappaB (NF-kappaB) activity is involved in the neuroprotective action of resveratrol against beta-amyloid-induced toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nitric oxide synthases: structure, function and inhibition
ALDERTON, W. K., COOPER, C. E., & KNOWLES, R. G. (2001) · Biochemical Journal · doi:10.1042/bj3570593 · Cited by 4,110 · cited 1×
“The small amount of NO produced by constitutive NOS, including eNOS and nNOS, is an important regulator of physiological homeostasis, whereas the large amount of NO produced by iNOS has been closely correlated with the pathophysiology in a variety of diseases and inflammation (33-35).”
Cited by
Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats
Jin, F., Wu, Q., Lu, Y.-F., Gong, Q.-H., & Shi, J.-S. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.10.005 · Cited by 384
Role of Polyphenols and Other Phytochemicals on Molecular Signaling
Upadhyay, S., & Dixit, M. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/504253 · Cited by 376
Resveratrol as a Therapeutic Agent for Neurodegenerative Diseases
Sun, A. Y., Wang, Q., Simonyi, A., & Sun, G. Y. (2010) · Molecular Neurobiology · doi:10.1007/s12035-010-8111-y · Cited by 329
Phytochemicals as inhibitors of NF-κB for treatment of Alzheimer’s disease
Seo, E.-J., Fischer, N., & Efferth, T. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2017.11.030 · Cited by 265
Rudrapal, M., Rakshit, G., Singh, R. P., Garse, S., Khan, J., & Chakraborty, S. (2024) · Antioxidants · doi:10.3390/antiox13040429 · Cited by 259
Griñán-Ferré, C., Bellver-Sanchis, A., Izquierdo, V., Corpas, R., Roig-Soriano, J., Chillón, M., Andres-Lacueva, C., Somogyvári, M., Sőti, C., Sanfeliu, C., et al. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101271 · Cited by 208
Antioxidant Effects of Resveratrol in Cardiovascular, Cerebral and Metabolic Diseases
Carrizzo, A., Forte, M., Damato, A., Trimarco, V., Salzano, F., Bartolo, M., Maciag, A., Puca, A. A., & Vecchione, C. (2013) · Food and Chemical Toxicology · doi:10.1016/j.fct.2013.07.021 · Cited by 203
Resveratrol Brain Delivery for Neurological Disorders Prevention and Treatment
Andrade, S., Ramalho, M. J., Pereira, M. D. C., & Loureiro, J. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01261 · Cited by 173
“Among these molecules are ROS, interleukins, nitric oxide (Kim et al., 2006; Huang et al., 2011), monocyte chemoattractant protein-1 and prostaglandin E2 (Kim et al., 2006).”
BackgroundDivino da Rocha, M., Pereira Dias Viegas, F., Cristina Campos, H., Carolina Nicastro, P., Calve Fossaluzza, P., Alberto Manssour Fraga, C., J. Barreiro, E., & Viegas, C. (2011) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152711794480429 · Cited by 126
Natural Phytochemicals in the Treatment and Prevention of Dementia: An Overview
Libro, R., Giacoppo, S., Soundara Rajan, T., Bramanti, P., & Mazzon, E. (2016) · Molecules · doi:10.3390/molecules21040518 · Cited by 107
“Aβ-induced rat C6 glioma cells anti-inflammatory iNOS, NO, COX-2, PGE2 Ó [62]”
BackgroundZhang, J., Feng, X., Wu, J., Xu, H., Li, G., Zhu, D., Yue, Q., Liu, H., Zhang, Y., Sun, D., et al. (2014) · BioFactors · doi:10.1002/biof.1149 · Cited by 50
Anti-Neuroinflammatory Potential of Polyphenols by Inhibiting NF-Κb to Halt Alzheimer's Disease
Uddin, M. S., Hasana, S., Ahmad, J., Hossain, M. F., Rahman, M. M., Behl, T., Rauf, A., Ahmad, A., Hafeez, A., Perveen, A., et al. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612826666201118092422 · Cited by 49
CRP gene variation affects early development of Alzheimer's disease-related plaques
Kok, E., Alanne-Kinnunen, M., Isotalo, K., Luoto, T., Haikonen, S., Goebeler, S., Perola, M., Hurme, M. A., Haapasalo, H., & Karhunen, P. J. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-96 · Cited by 16
“Current understanding indicates that the neuropathological hallmarks, senile plaques (SP) and neurofibrillary tangles (NFT) develop within the brain, interrupting neuronal signalling and causing the irreversible symptoms of memory impairment and gradual cognitive decline [1,2].”
BackgroundBai, Q., & Zhao, Z. (2022) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2147 · Cited by 12
Metadata
- Authors
- Kim, Y., Lim, S.-Y., Rhee, S.-H., Park, K., Kim, C.-H., Choi, B., Lee, S., Park, Y.-M., & Choi, Y.
- Venue
- International Journal of Molecular Medicine
- Publisher
- Spandidos Publications
- Published
- 2006-06-01
- Volume
- 17
- Issue
- 6
- Pages
- 1069-75
- ISSN
- 1107-3756 (ISSN-L)
- 1791-244X
- OpenAlex
- W2055930420
- Cited by
- 88
- References
- 1
- FWCI
- 3.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.